SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia

European Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2012, Pages 273-279

  Santos, Paulo Caleb Junior Lima ^a   Gagliardi, Ana Carolina Moron ^a   Miname, Márcio Hiroshi ^a   Chacra, Ana Paula ^a   Santos, Raul Dias ^a   Krieger, Jose Eduardo ^a   Pereira, Alexandre Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atorvastatin; Creatine kinase; Haplotypes; Myalgia; Pharmacogenetic; SLCO1B1

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BRAZILIAN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ETHNIC GROUP; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HIGH RESOLUTION MELTING ANALYSIS; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; SLCO1B1 GENE; TREATMENT DURATION;

ADULT; AGED; BRAZIL; FEMALE; GENETIC DISEASES, INBORN; HAPLOTYPES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; PYRROLES;

EID: 84857035975     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1125-1     Document Type: Article

References (27)

1. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins R Simes 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 1267 1278 10.1016/S0140-6736(05)67394-1 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
2. A Ghatak O Faheem PD Thompson 2010 The genetics of statin-induced myopathy Atherosclerosis 210 2 337 343 10.1016/j.atherosclerosis.2009.11.033 20042189 10.1016/j.atherosclerosis.2009.11.033 1:CAS:528:DC%2BC3cXmslGnurc%3D
3. E Link S Parish J Armitage L Bowman S Heath F Matsuda I Gut M Lathrop R Collins 2008 SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 8 789 799 10.1056/NEJMoa0801936 18650507 10.1056/NEJMoa0801936 1:CAS:528:DC%2BD1cXhtVShtbnF
4. PD Thompson PM Clarkson RS Rosenson 2006 An assessment of statin safety by muscle experts Am J Cardiol 97 8A 69C 76C 10.1016/j.amjcard.2005.12.013 16581332 10.1016/j.amjcard.2005.12.013 1:CAS:528:DC%2BD28XkvF2gsro%3D
5. J Armitage 2007 The safety of statins in clinical practice Lancet 370 9601 1781 1790 10.1016/S0140-6736(07)60716-8 17559928 10.1016/S0140-6736(07) 60716-8 1:CAS:528:DC%2BD2sXhtlCrtLnM (Pubitemid 350137473)
6. AM Gotto Jr 2006 Statins, cardiovascular disease, and drug safety Am J Cardiol 97 8A 3C 5C 10.1016/j.amjcard.2005.12.005 16581326
7. M Law AR Rudnicka 2006 Statin safety: a systematic review Am J Cardiol 97 8A 52C 60C 10.1016/j.amjcard.2005.12.010 16581329 10.1016/j.amjcard.2005.12.010 1:CAS:528:DC%2BD28XkvF2gsr4%3D
8. GA Nichols CE Koro 2007 Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients Clin Ther 29 8 1761 1770 10.1016/j.clinthera.2007.08.022 17919557 10.1016/j.clinthera.2007.08.022 1:CAS:528:DC%2BD2sXhtFyjt7nP (Pubitemid 47494553)
9. LR Brunham PJ Lansberg K Zhang F Miao C Carter GK Hovingh H Visscher JW Jukema AF Stalenhoef CJ Ross BC Carleton JJ Kastelein MR Hayden 2011 Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin Pharmacogenomics J 10.1038/tpj.2010.92 21243006
10. D Voora SH Shah I Spasojevic S Ali CR Reed BA Salisbury GS Ginsburg 2009 The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 17 1609 1616 10.1016/j.jacc.2009.04.053 19833260 10.1016/j.jacc.2009.04.053 1:CAS:528:DC%2BD1MXhsVGnu77E
11. E Aklillu S Mugusi E Ngaimisi MM Hoffmann S Konig V Ziesensitz G Mikus WE Haefeli J Weiss 2011 Frequency of the SLCO1B1 388A > G and the 521 T > C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method Eur J Clin Pharmacol 10.1007/s00228-011-1065-9 21630030
12. M Niemi MK Pasanen PJ Neuvonen 2011 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake Pharmacol Rev 63 1 157 181 10.1124/pr.110.002857 21245207 10.1124/pr.110.002857 1:CAS:528:DC%2BC3MXjslGis7w%3D
13. MK Pasanen H Fredrikson PJ Neuvonen M Niemi 2007 Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 82 6 726 733 10.1038/sj.clpt.6100220 17473846 10.1038/sj.clpt.6100220 1:CAS:528:DC%2BD2sXht1ymu7jM (Pubitemid 350114817)
14. MK Pasanen M Neuvonen PJ Neuvonen M Niemi 2006 SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet Genomics 16 12 873 879 10.1097/01.fpc.0000230416.82349.90 17108811 10.1097/01.fpc. 0000230416.82349.90 1:CAS:528:DC%2BD28Xht1SmtrvP (Pubitemid 44772805)
15. JW Deng IS Song HJ Shin CW Yeo DY Cho JH Shon JG Shin 2008 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 Pharmacogenet Genomics 18 5 424 433 10.1097/FPC. 0b013e3282fb02a3 18408565 10.1097/FPC.0b013e3282fb02a3 1:CAS:528: DC%2BD1cXksFynu7g%3D (Pubitemid 351535943)
16. M Iwai H Suzuki I Ieiri K Otsubo Y Sugiyama 2004 Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C) Pharmacogenetics 14 11 749 757 15564882 10.1097/00008571-200411000- 00006 1:CAS:528:DC%2BD2cXhtVais7%2FE (Pubitemid 39552790)
17. Y Kameyama K Yamashita K Kobayashi M Hosokawa K Chiba 2005 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 15 7 513 522 15970799 10.1097/01.fpc.0000170913.73780.5f 1:CAS:528:DC%2BD2MXltlGju7k%3D (Pubitemid 41017600)
18. M Tsuda-Tsukimoto T Maeda T Iwanaga T Kume I Tamai 2006 Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035 Pharm Res 23 11 2646 2656 10.1007/s11095-006-9102-6 16969695 10.1007/s11095-006-9102-6 1:CAS:528:DC%2BD28XhtFKgu7nK (Pubitemid 44691611)
19. R Huijgen MN Vissers JC Defesche PJ Lansberg JJ Kastelein BA Hutten 2008 Familial hypercholesterolemia: current treatment and advances in management Expert Rev Cardiovasc Ther 6 4 567 581 10.1586/14779072.6.4.567 18402545 10.1586/14779072.6.4.567 1:CAS:528:DC%2BD1cXksFynsLs%3D
20. AH Pijlmann R Huijgen SN Verhagen BP Imholz AH Liem JJ Kastelein EJ Abbink AF Stalenhoef FL Visseren 2010 Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands Atherosclerosis 209 1 189 194 10.1016/j.atherosclerosis.2009.09.014 10.1016/j.atherosclerosis.2009.09.014
21. RR Williams SC Hunt MC Schumacher RA Hegele MF Leppert EH Ludwig PN Hopkins 1993 Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics Am J Cardiol 72 2 171 176 8328379 10.1016/0002-9149(93)90155-6 1:STN:280:DyaK3szhvVOnuw%3D%3D (Pubitemid 23205873)
22. RR Williams MC Schumacher GK Barlow SC Hunt JL Ware M Pratt BD Latham 1993 Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah Am J Cardiol 72 10 18D 24D 8213492 10.1016/0002-9149(93)90006-X 1:STN:280: DyaK2c%2Fis1Ojtw%3D%3D (Pubitemid 23286498)
23. RO Alvim SR Freitas NE Ferreira PC Santos RS Cunha JG Mill JE Krieger AC Pereira 2010 APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population Lipids Health Dis 9 1 128 10.1186/1476-511X-9-128 21059196 10.1186/1476-511X-9-128
24. PC Santos RD Cancado AC Pereira IT Schettert RA Soares RA Pagliusi RD Hirata AC Teixeira MS Figueiredo CS Chiattone JE Krieger EM Guerra-Shinohara 2011 Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients Blood Cells Mol Dis 46 4 302 307 10.1016/j.bcmd.2011.02. 008 21411349 10.1016/j.bcmd.2011.02.008 1:CAS:528:DC%2BC3MXksFeksr0%3D
25. PC Santos RA Soares DB Santos RM Nascimento GL Coelho JC Nicolau JG Mill JE Krieger AC Pereira 2011 CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population BMC Med Genet 12 13 10.1186/1471-2350-12-13 21247447 10.1186/1471-2350-12-13 1:CAS:528:DC%2BC3MXht1Kqsb8%3D
26. L Puccetti F Ciani A Auteri 2010 Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study Atherosclerosis 211 1 28 29 10.1016/j.atherosclerosis.2010.02.026 20347093 10.1016/j.atherosclerosis.2010.02.026 1:CAS:528:DC%2BC3cXos1yiurs%3D
27. PC Santos RO Alvim NE Ferreira R de Sa Cunha JE Krieger JG Mill AC Pereira 2011 Ethnicity and arterial stiffness in Brazil Am J Hypertens 24 3 278 284 10.1038/ajh.2010.244 21183929 10.1038/ajh.2010.244